Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome

CARLSBAD, Calif. , Feb. 15, 2024 /PRNewswire/ —  Ionis Pharmaceuticals , Inc.  (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to the investigational medicine olezarsen for the treatment of familial chylomicronemia syndrome (FCS),